08.06.2021          P                      1,000         17.9500        EUR           XETR 
 17:36:09 
 
 08.06.2021          P                      10,000        17.9500        EUR           XETR 
 17:36:09 
 
 10.06.2021          P                      801           17.6500        EUR           XETR 
 10:36:50 
 
 10.06.2021          P                      263           17.7000        EUR           XETR 
 10:36:50 
 
 10.06.2021          P                      33            17.8000        EUR           XETR 
 12:42:42 
 
 10.06.2021          P                      781           17.8500        EUR           XETR 
 12:42:42 
 
 10.06.2021          P                      10            17.8000        EUR           XETR 
 12:45:37 
 
 10.06.2021          P                      956           17.8500        EUR           XETR 
 12:45:37 
 
 10.06.2021          P                      961           17.9000        EUR           XETR 
 12:45:37 
 
 10.06.2021          P                      156           17.9500        EUR           XETR 
 12:45:37 
 
 10.06.2021          P                      353           17.9500        EUR           XETR 
 13:14:37 
 
 10.06.2021          P                      26            18.0000        EUR           XETR 
 13:14:37 
 
 10.06.2021          P                      500           17.7500        EUR           XETR 
 14:28:37 
 
 10.06.2021          P                      344           17.9000        EUR           XETR 
 14:28:37 
 
 10.06.2021          P                      24            17.9500        EUR           XETR 
 14:28:37 
 
 10.06.2021          P                      25,000        18.2000        EUR           XETR 
 17:36:25 
 
 
 
 Sum           Aggregated Weighted price  Currency code 
               volume                     (ISO 4217) 
               (pieces) 
 
               180,908    17.8708         EUR

IMPORTANT NOTICE

These materials may not be, directly or indirectly, published, distributed or transmitted in or into the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of Apontis Pharma AG (the "Company") in the United States, Australia, Canada, Japan or any other jurisdiction in which such offer or solicitation is unlawful. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). There will be no public offering of the securities in the United States. The Securities of the Company have not been, and will not be, registered under the Securities Act. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.), or (iii) to whom an invitation or inducement to engage in an investment activity (within the meaning of section 21 of the United Kingdom Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. The securities have already been sold. -----------------------------------------------------------------------------------------------------------------------

2021-06-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      APONTIS PHARMA AG 
              Alfred-Nobel-Str. 10 
              40789 Monheim 
              Germany 
E-mail:       info@apontis-pharma.de 
Internet:     https://apontis-pharma.de/ 
ISIN:         DE000A3CMGM5 
WKN:          A3CMGM 
Listed:       Regulated Unofficial Market in Frankfurt (Scale) 
EQS News ID:  1206816 
 
End of News   DGAP News Service 
=------------

1206816 2021-06-10


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1206816&application_name=news

(END) Dow Jones Newswires

June 10, 2021 15:21 ET (19:21 GMT)